Part,  Chapter, Paragraph

  1    I,     3.  4        |        Available at: htt ~ ~Prioux F (1993): L’infecondité en
  2   II,     4.  3        |            590-597.~ ~Sullivan, D. F. (1971): A single index
  3   II,     5.  2.  5    |          Poli A et al, 2008; Sacks F et al, 2001); the hypolipidemic
  4   II,     5.  2.  6    |  Djordjević BD, Dontas AS, Fidanza F, Karvonen MJ, Kimura N,
  5   II,     5.  2.  6    |           256: 2823-2828.~Turnbull F; Blood Pressure Lowering
  6   II,     5.  2.  7    |            Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais
  7   II,     5.  3.  9    |           3.8 References~ ~Berrino F, De Angelis R, Sant M, Rosso
  8   II,     5.  3.  9    |            Santaquilani M, Berrino F, EUROCARE Working Group (
  9   II,     5.  3.  9    |      Stiller C, Kaatsch P, Berrino F, Terenziani M, the EUROCARE
 10   II,     5.  3.  9    |      v28-v40.~ ~Micheli A, Berrino F, Paci E, Verdecchia A, Pierotti
 11   II,     5.  3.  9    |           P, Verdecchia A, Berrino F, Coleman M (2003): Cancer
 12   II,     5.  3.  9    |         116-118.~ ~Parkin DM, Bray F, Ferlay J, Pisani P (2005):
 13   II,     5.  3.  9    |        Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli
 14   II,     5.  4.  8    |             Cunningham S, Sullivan F and Morris A (2001), on
 15   II,     5.  4.  8    |         Massi Benedetti M, Carinci F, Orsini Federici M (2006),
 16   II,     5.  5.Int(10)|                              Myers F, McCollam A, Woodhouse A (
 17   II,     5.  5.Int(12)|             Östlin, M. Danielsson, F. Diderichsen, A. Härenstam
 18   II,     5.  5.Int(15)|            I, Prince MJ, Reischies F, Roelands M, Skoog I, Turrina
 19   II,     5.  5.  3    |             De Henauw S , Gottrand F , De Bourdeaudhuij I, Gonzalez-Gross
 20   II,     5.  5.  3    |        Ruhrmann S, Schultze-Lutter F, Salokangas RK, Linszen
 21   II,     5.  5.  3    |         Wrigley S, Jackson H, Judd F, Komiti A (2005): Role of
 22   II,     5.  5.  3    |        1187-1194.~Nashef L, Walker F, Allen P, et al (1996):
 23   II,     5.  5.  3    |          by: Aldenkamp A, Dreifuss F, Renier O, et al) Boca Raton,
 24   II,     5.  5.  3    |       Elsevier, Amsterdam.~Ranzato F, Perini P, Tzintzeva E et
 25   II,     5.  5.  3    |             de Rijk MC, Grigoletto F, Melcon MO, Breteler MM,
 26   II,     5.  5.  3    |         Perissinotto E, Grigoletto F, Amaducci L, Inzitari D (
 27   II,     5.  5.  3    |      Benito-Leon J, Bermejo-Pareja F, Rodriguez J, Molina JA,
 28   II,     5.  5.  3    |            251(3):340-345.~Bermejo F, Gabriel R, Vega S, Morales
 29   II,     5.  5.  3    |            A, Cabezas C, Rodriguez F, de Pedro-Cuesta J (2002):
 30   II,     5.  5.  3    |             Wait S, Moutard-Martin F, Dujardin M, Ziegler M (
 31   II,     5.  5.  3    |             Bartoloni A, Bartalesi F, Gamboa Barahon H, Giuffrida
 32   II,     5.  5.  3    |          Deuschl G, Forstl H, Henn F, Heuser I, Oertel W, Reichmann
 33   II,     5.  5.  3    |         Whetten-Goldstein K, Sloan F, Kulas E, Cutson T, Schenkman
 34   II,     5.  6.  6    |           C, Bolosiu HD, Breedveld F, Dougados M, Emery P, Ferraccioli
 35   II,     5.  6.  6    |         Lindsey S, Pincus T, Wolfe F (1992): The American College
 36   II,     5.  6.  6    |       Pillemer SR, Steen VD, Wolfe F (1998): Estimates of the
 37   II,     5.  6.  6    |            MA, de Regt EB, Andries F, van Agt HM, Bijl RV, de
 38   II,     5.  6.  6    |            Head J, Canner R, North F, Marmot M (1995): Sickness
 39   II,     5.  7.  7    |          94):S28-S35.~Garcia-Lopez F. Epirce. Epidemiologia de
 40   II,     5.  7.  7    |         Hsu CY, Vittinghoff E, Lin F, Shlipak MG (2004): The
 41   II,     5.  7.  7    |          Otero A, Gayoso P, Garcia F, de Francisco AL (2005):
 42   II,     5.  7.  7    |           P, Vecchio LD, Locatelli F (2007): International Study
 43   II,     5.  8.  7    |      Corsico A, Sunyer J, Neukirch F, Kunzli N, Leynaert B, Janson
 44   II,     5.  8.  7    |              Jansson SA, Andersson F, Borg S, Ericsson A, Jonsson
 45   II,     5.  8.  7    |         Gingles J, Shepherd R, Kee F, Patterson C, MacMahon J (
 46   II,     5.  8.  7    |          Errico A, Urrutia I, Payo F, Olivieri M, Villani S,
 47   II,     5.  8.  7    |           G, Pedreschi M, Pistelli F, Di Pede F, Baldacci S,
 48   II,     5.  8.  7    |   Pedreschi M, Pistelli F, Di Pede F, Baldacci S, Carrozzi L,
 49   II,     5.  9.  4    |            male to female ratio (M:F) significantly narrowed
 50   II,     5.  9.  7    |        1053.~ ~Baiardini I, Braido F, Brandi S, Canonica GW (
 51   II,     5.  9.  7    |         Allergy 62:301-9.~ ~Braido F, Baiardini I, Brandi S (
 52   II,     5. 11.  3    |         2003; 49:107108.~R Silva, F Pere a, O Bord o, E Silva,
 53   II,     5. 11.  7    |         2003;30:123131.~ ~Dalgard F, Svensson A, et al (2003):
 54   II,     5. 11.  7    |         S61):1-6.~ ~Ferlay J, Bray F, Pisani P, Parkin DM (2001):
 55   II,     5. 11.  7    |   Dermatitis 1985;13:29-48.~ ~Levi F, Te VC, Randimbison L et
 56   II,     5. 12.  7    |       Nainan OV, McQuillan GM, Gao F, Moyer LA,~Kaslow RA, Margolis
 57   II,     5. 12.  7    |          777-782.~ ~Bsetti C, Levi F, Lucchini F, Zatonski WA,
 58   II,     5. 12.  7    |         Bsetti C, Levi F, Lucchini F, Zatonski WA, Negri E, La
 59   II,     5. 12.  7    |          351.~ ~La Vecchia C, Levi F, Lucchini F, Franceschi
 60   II,     5. 12.  7    |        Vecchia C, Levi F, Lucchini F, Franceschi S, Negri E (
 61   II,     6.  4.  5    |   sanctions and reporting systems; f) phase out and replace antimicrobial
 62   II,     7.  7        |            K, Sharma G.~ ~Racioppi F, Eriksson L, Tingvall C,
 63   II,     7.  7        |       Shields N, Sethi D, Racioppi F, Yordi Aguirre I, Baumgarten
 64   II,     8.  2.  1    |            Haveman, M., Jørgensen, F., & OFarrell, L., (2005).
 65   II,     8.  2.  2    |        Nucci C, Cedrone C, Culasso F, Ricci F, Cesareo M, Corsi
 66   II,     8.  2.  2    |        Cedrone C, Culasso F, Ricci F, Cesareo M, Corsi A and
 67   II,     9.  1.  1    |             C=core, R=recommended, F=for further development)~ ~
 68   II,     9.  1.  1    |           APGAR score at 5 minutes~F: Causes of perinatal death/
 69   II,     9.  1.  1    |            to congenital anomalies~F: Prevalence of cerebral
 70   II,     9.  1.  1    |       Prevalence of cerebral palsy~F: Prevalence of hypoxic-ischemic
 71   II,     9.  1.  1    |   hypoxic-ischemic encephalopathy~ F: Prevalence of late induced
 72   II,     9.  1.  1    |            late induced abortions~ F: Severe neonatal morbidity
 73   II,     9.  1.  1    |         among babies at high risk~ F: Neonatal screening policies~
 74   II,     9.  1.  1    |          severe maternal morbidity~F: Prevalence of trauma to
 75   II,     9.  1.  1    |          of trauma to the perineum~F: Prevalence of faecal incontinence~
 76   II,     9.  1.  1    |  Prevalence of faecal incontinence~F: Postpartum depression~Population
 77   II,     9.  1.  1    | Distribution of motherseducation~F: Distribution of mothers'
 78   II,     9.  1.  1    |            breast-feeding at birth~F: Indicator of support to
 79   II,     9.  1.  1    |      Indicator of support to women~F: Indicator of maternal satisfaction~
 80   II,     9.  1.  1    |           of maternal satisfaction~F: Births attended by midwives~
 81   II,     9.  1.  1    |        Births attended by midwives~F: Births without medical
 82   II,     9.  1.  2    |       following prenatal diagnosis f) linkage between different
 83   II,     9.  1.  2    |          specific genetic risks.~ ~f) The phenomenon of older
 84   II,     9.  1.  2    |           369, pp 641-642.~Bianchi F, Bianca S, Linzalone N,
 85   II,     9.  1.  2    |            Ha M-C, Ayme S, Bianchi F, Calzolari E, De Walle H,
 86   II,     9.  1.  2    |        Feijoo M, Lillis D, Bianchi F (2005): "Trends and Geographic
 87   II,     9.  2.  7    |          11, 313-326, 1976.~ ~Levi F, La Vecchia C, Negri E,
 88   II,     9.  2.  7    |       Vecchia C, Negri E, Lucchini F (2001): Childhood cancer
 89   II,     9.  2.  7    |            C, Johnson A, Alderdice F, Petty T, Macfarlane A (
 90   II,     9.  3.  1    |       Mazzeha, C. Keech. M. Hobbs, F.D.R. Fourcade R. Kiemeney ,
 91   II,     9.  3.  1    |              Falzon D and Belghiti F (2007): Tuberculosis – still
 92   II,     9.  3.  1    |            C, Johnson A, Alderdice F, Petty T, Macfarlane A (
 93   II,     9.  3.  2    |              Philibert M, Boisbras F, Bouvier-Colle M-H (2006):
 94   II,     9.  3.  3    |            3.6. References~ ~Amaro F, Frazão C, Pereire ME, da
 95   II,     9.  3.  3    |       Ducot B, Johnson AM, Le Pont F, Wellings K, Spira A, Field
 96   II,     9.  3.  3    |        France.~Bochow M, Chiarotti F, davies P, Dubois-Arber
 97   II,     9.  3.  3    |             davies P, Dubois-Arber F, Dür W, Fouchard J, Gruet
 98   II,     9.  3.  3    |           Dür W, Fouchard J, Gruet F, McManus T, Markert S, Sandfort
 99   II,     9.  3.  3    |          18 :1867-73.~Dubois-Arber F, Jeannin A, Konings E, Paccaud
100   II,     9.  3.  3    |      Jeannin A, Konings E, Paccaud F (1997): Increased condom
101   II,     9.  3.  3    |     Cousins G, Donnelly C, Mulcahy F, Conroy R (2006): The Irish
102   II,     9.  3.  3    |       Health 35:298-305~Serbanescu F, Morris L, Marin M (2001):
103   II,     9.  4.  7    |      Medicine; 3(3):94-98~ ~Mahar, F (2003): Sexually transmitted
104   II,     9.  5.  6    |          Danielsson M, Diderichsen F, Härenstam A, Lindberg G).
105   II,     9.  5.  6    |            C, Johnson A, Alderdice F, Petty T,Macfarlane A (1996):
106   II,     9.  5.  6    |        Garamond Press Ltd.~ ~Myers F, McCollam A, Woodhouse A (
107  III,    10.  2.  1    |   Kvinnsland S, La Vecchia C, Levi F, McVie JC, Maisonneuve P,
108  III,    10.  2.  1    |            Newton Bishop J, Oleari F, Perrin P, Quinn M, Richards
109  III,    10.  2.  1    |           B, Luczynska C, Neukirch F, Vermeire P, Wjst M and
110  III,    10.  2.  1    |           A, Nilsson JA, Lindgarde F (2002): Prevention of alcohol-related
111  III,    10.  2.  1    |          484.~ ~Kunst AE, Groenhof F, Mackenbach JP, EU Working
112  III,    10.  2.  1    |           Heimerson I, Diderichsen F (2005): Socioeconomic Differentials
113  III,    10.  2.  1    |            277.~ ~Kaner EFS, Beyer F, Dickinson HO, Pienaar E,
114  III,    10.  2.  1    |            HO, Pienaar E, Campbell F, Schlesinger C, Heather
115  III,    10.  2.  1    |            the difference in daily F tooth-brushing twice of
116  III,    10.  2.  1    |            2.1.5.1. Children Daily F Toothbrushing Frequency
117  III,    10.  2.  1    |          AK, Kallestal C, Lagerlof F, Lingstrom P, Mejare I,
118  III,    10.  2.  1    |             Bostrom G, Diderichsen F (1997): Socioeconomic differentials
119  III,    10.  2.  1    |  Epidemiology 26:860866.~ ~Branca F, Nikogosian H, Lobstein
120  III,    10.  2.  1    |            October 2007).~ ~Branca F, Nikogosian H, Lobstein
121  III,    10.  2.  1    |    Nutrition 61:743-751.~ ~Paccaud F, Wietlisbach V, Rickenbach
122  III,    10.  2.  1    |          Rodler I, Bíró L, Greiner F, Zajkás G, Szórád I, Varga
123  III,    10.  2.  1    |   Castetbon K, Arnault N, Bellisle F, Romano MC, Lehingue Y,
124  III,    10.  2.  1    |            Darnton-Hill I, Delange F. Iodine deficiency in Europe:
125  III,    10.  2.  1    |         Overvad K, Clavel-Chapelon F, Casagrande C, Riboli E (
126  III,    10.  2.  1    |           E, Zavitsanos X, Berrino F, Sacerdote C, Ocke MC, Peeters
127  III,    10.  2.  1    |      Tjonneland A, Clavel-Chapelon F, Linseisen J, Schulz M,
128  III,    10.  2.  1    |      Tjonneland A, Clavel-Chapelon F, Linseisen J, Haftenberger
129  III,    10.  2.  1    |      Tjonneland A, Clavel-Chapelon F, Kesse E, Miller AB, Schulz
130  III,    10.  2.  1    |      Tjonneland A, Clavel-Chapelon F, Miller AB, Klipstein-Grobusch
131  III,    10.  2.  1    |          Stripp C, Clavel-Chapelon F, Kesse E, Boeing H, Klipstein-Grobusch
132  III,    10.  2.  1    |      Tjonneland A, Clavel-Chapelon F, Thiebaut A, Miller AB,
133  III,    10.  2.  1    |      Tjonneland A, Clavel-Chapelon F, Linseisen J, Klipstein-Grobusch
134  III,    10.  2.  4    |            Wichmann H E, Wienker T F, Schulze J, Schwarz P E,
135  III,    10.  2.  4    |          Zuber M, Köchli OR, Mross F, Dieterich H, Moch H, Mihatsch
136  III,    10.  3.  1    |            divided into frequency (f) bands, namely: radio frequency (
137  III,    10.  3.  1    |        Fields (RF fields, 100 kHz <f 300 GHz), including epidemiologic,
138  III,    10.  3.  1    |        Fields, (IF fields, 300 Hz <f 100 kHz), experimental and
139  III,    10.  3.  1    |            magnetic fields (ELF, 0<f 300 Hz) the previous conclusion
140  III,    10.  3.  1    |          2006, Tampere, 2006.~Bray F, Sankila R, Ferlay J, Parkin
141  III,    10.  3.  1    |          JM, Baysson H, Bochicchio F, Deo H, Falk R, Forastiere
142  III,    10.  3.  1    |          Deo H, Falk R, Forastiere F, Hakama M, Heid I, Kreienbrock
143  III,    10.  3.  1    |  Kreienbrock L, Kreuzer M, Lagarde F, Mäkeläinen I, Muirhead
144  III,    10.  3.  2    |          Ma, S Caroli, A Alimonti, F Petrucci, B Bocca, P Schramel,
145  III,    10.  4.  1    |        2005.~ ~Holland, M.,Hurley, F., Pye S., Watkiss P. and
146  III,    10.  4.  2    |            in case of emergencies; f) consumer information as
147  III,    10.  4.  2(40)|                         Commission f the European Communities:
148  III,    10.  4.  2    |           for in this Regulation; (f) that they have contingency
149  III,    10.  4.  2    |                   Inoue, K, Okada, F, Ito, R, Kato, S, Sasaki,
150  III,    10.  4.  2    |            Uno, A, Saijo, Y, Sata, F, Yoshimura, Y, Kishi, R,
151  III,    10.  4.  3    |     Letters 164S: S324-S325~Valent F, et al (2004): Burden of
152  III,    10.  5.  1    |             15:67.~Miller DM, Meek F, (2004): Cost and efficacy
153   IV,    11.  6.  5    |     Perleth M, Drummond M, Gürtner F, Jørgensen T, Jovell A,
154   IV,    11.  6.  5    |          2007.~ ~Gosden T, Forland F et al. (2006): Cochrane
155   IV,    12. 10        |        warning’’ (ESA AO/1-4914/05/F/IZ, Duration: 01/07/2006-